Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WHO SOLIDARITY Finland: Artesunate, Imatinib and Infliximab in hospitalized COVID-19
2020-001784-88Phase 3Completed
- Sponsor
- University of Helsinki
- Start
- Apr 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of artesunate, imatinib and infliximab in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by University of Helsinki. Primary endpoint: In-hospital all-cause mortality (overall). Started Apr 2020; status: completed.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001784-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001784-88.